Long-term foliow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-hodgkin's lymphoma

Joseph P. Colgan, Janet Andersen, Thomas M. Habermann, John D. Earle, Michael J. O'connell, Richard S. Neman, Risa B. Mann, John H. Glickk

Research output: Contribution to journalArticle

33 Scopus citations

Abstract

The Eastern Cooperative Oncology Group (ECOG) conducted a phase II trial in adult patients with lymphoblastic non-Hodgkin's lymphoma. Thirty-nine patients with no central nervous system (CNS) involvement were treated with an induction cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)/L-asparaginase regimen and CNS prophylaxis that included intrathecally administered methotrexate given 6 times and 24 Gy midplane cranial radiation in 12 fractions. Thirty-one patients (79% achieved a complete remission (CR). Of the 31 patients with CRs, 12 relapsed (39% CNS relapse occurred in three patients. All patients who entered a CR were treated with maintenance CHOP, cytosine arabinoside (Ara-C), and methotrexate and subsequently with Ara-C and methotrexate. Life-threatening leukopenia or thrombocytopenia was experienced in 69% of patients in the induction phase and in 70% in the maintenance phase. Nineteen of 39 patients (49% remain in CR with a follow-up to 9 years. Bone marrow involvement was associated with a significantly worse survival (P = 0.03).

Original languageEnglish (US)
Pages (from-to)291-296
Number of pages6
JournalLeukemia and Lymphoma
Volume15
Issue number3-4
DOIs
StatePublished - Jan 1 1994

Keywords

  • CHOP/L-asparaginase regimen
  • CNS prophylaxis
  • Lymphoblastic
  • Non-Hodgkin's lymphoma
  • Phase II trial

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Long-term foliow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-hodgkin's lymphoma'. Together they form a unique fingerprint.

  • Cite this